Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 2
1983 4
1988 1
1989 1
1991 1
1993 1
1994 1
1995 1
1997 1
1998 3
1999 5
2000 2
2001 2
2002 2
2003 1
2004 3
2005 4
2006 2
2008 1
2009 2
2010 2
2011 4
2012 3
2013 2
2014 7
2015 8
2016 5
2017 13
2018 8
2019 10
2020 7
2021 7
2022 17
2023 17
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Colon Adenocarcinoma"
Page 1
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J; SUNLIGHT Investigators. Prager GW, et al. N Engl J Med. 2023 May 4;388(18):1657-1667. doi: 10.1056/NEJMoa2214963. N Engl J Med. 2023. PMID: 37133585 Clinical Trial.
The median time to worsening of the ECOG performance-status score from 0 or 1 to 2 or more was 9.3 months in the combination group and 6.3 months in the FTD-TPI group (hazard ratio, 0.54; 95% CI, 0.43 to 0.67). CONCLUSIONS: Among patients with refractory metastatic colorec …
The median time to worsening of the ECOG performance-status score from 0 or 1 to 2 or more was 9.3 months in the combination group and 6.3 m …
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Dasari A, et al. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. Lancet. 2023. PMID: 37331369 Clinical Trial.
We included patients aged 18 years or older (20 years in Japan) with histologically or cytologically documented metastatic colorectal adenocarcinoma who had received all current standard approved cytotoxic and targeted therapies and progressed on or were intolerant to trif …
We included patients aged 18 years or older (20 years in Japan) with histologically or cytologically documented metastatic colorectal ade …
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS; MOUNTAINEER investigators. Strickler JH, et al. Lancet Oncol. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X. Lancet Oncol. 2023. PMID: 37142372 Clinical Trial.
We assessed the activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer. ...This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metasta …
We assessed the activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresec …
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, Aubin F, Koski SL, Wei AC, Magoski NM, Tu D, O'Callaghan CJ. Chen EX, et al. JAMA Oncol. 2020 Jun 1;6(6):831-838. doi: 10.1001/jamaoncol.2020.0910. JAMA Oncol. 2020. PMID: 32379280 Free PMC article. Clinical Trial.
IMPORTANCE: Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H). ...Eligible patients had histologically confirmed adenocarcinoma …
IMPORTANCE: Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other …
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Bekaii-Saab TS, et al. Lancet Oncol. 2019 Aug;20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4. Epub 2019 Jun 28. Lancet Oncol. 2019. PMID: 31262657 Free PMC article. Clinical Trial.
BACKGROUND: Regorafenib confers an overall survival benefit in patients with refractory metastatic colorectal cancer; however, the adverse event profile of regorafenib has limited its use. ...METHODS: In this randomised, multicentre, open-label, phase 2 study done in 39 ou …
BACKGROUND: Regorafenib confers an overall survival benefit in patients with refractory metastatic colorectal cancer; however, the ad …
Refractory distal ulcerative colitis: is proctocolectomy always necessary?
Carvello M, Montorsi M, Spinelli A. Carvello M, et al. Dig Dis. 2014;32 Suppl 1:110-5. doi: 10.1159/000367860. Epub 2014 Dec 17. Dig Dis. 2014. PMID: 25531362 Review.
Refractory distal ulcerative colitis (RDUC) is defined as persistence of symptoms caused by endoscopically proven colonic inflammation located at the rectum or left colon despite oral/topical steroids and 5-ASA. ...Moreover, patients with long-standing ulcera …
Refractory distal ulcerative colitis (RDUC) is defined as persistence of symptoms caused by endoscopically proven colonic infl …
Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.
Riesco-Martinez MC, Sanchez-Torre A, Garcia-Carbonero R. Riesco-Martinez MC, et al. Expert Opin Investig Drugs. 2017 Nov;26(11):1295-1305. doi: 10.1080/13543784.2017.1385762. Epub 2017 Oct 6. Expert Opin Investig Drugs. 2017. PMID: 28965421 Review.
Recent results from the LUME-Colon 1 pivotal phase III trial showed only a marginal increase in progression free survival over placebo in refractory mCRC patients, with a toxicity profile similar to other antiangiogenic agents, and no benefit in overall survival. .. …
Recent results from the LUME-Colon 1 pivotal phase III trial showed only a marginal increase in progression free survival over placeb …
Inflammatory bowel disease in liver transplanted patients.
Filipec Kanizaj T, Mijic M. Filipec Kanizaj T, et al. World J Gastroenterol. 2017 May 14;23(18):3214-3227. doi: 10.3748/wjg.v23.i18.3214. World J Gastroenterol. 2017. PMID: 28566881 Free PMC article. Review.
Anti-tumor necrosis factor alpha appears to be efficient for refractory IBD. Due to potential side effects it needs to be applied with caution. ...Annual colonoscopies are recommended as surveillance and precaution of colonic malignancies....
Anti-tumor necrosis factor alpha appears to be efficient for refractory IBD. Due to potential side effects it needs to be applied wit …
State-of-the-art surgery for Crohn's disease: Part II-colonic Crohn's disease and associated neoplasms.
Macleod A, Kavalukas SL, Scheurlen KM, Galandiuk S. Macleod A, et al. Langenbecks Arch Surg. 2022 Nov;407(7):2595-2605. doi: 10.1007/s00423-022-02572-y. Epub 2022 Jun 22. Langenbecks Arch Surg. 2022. PMID: 35729401 Review.
Continuing from Part I of this series (small intestine/ileal disease), we focus next on colonic Crohn's disease and associated neoplasms. We will first review the surgical management of medical-refractory Crohn's colitis and its complications and then examine …
Continuing from Part I of this series (small intestine/ileal disease), we focus next on colonic Crohn's disease and associated neo …
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
Signorelli C, Calegari MA, Basso M, Anghelone A, Lucchetti J, Minelli A, Angotti L, Zurlo IV, Schirripa M, Chilelli MG, Morelli C, Dell'Aquila E, Cosimati A, Gemma D, Ribelli M, Emiliani A, Corsi DC, Arrivi G, Mazzuca F, Zoratto F, Morandi MG, Santamaria F, Saltarelli R, Ruggeri EM. Signorelli C, et al. Curr Oncol. 2023 Jun 4;30(6):5456-5469. doi: 10.3390/curroncol30060413. Curr Oncol. 2023. PMID: 37366896 Free PMC article.
BACKGROUND: Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. ...
BACKGROUND: Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact th …
144 results